Recurrent Renal Cell Cancer
51
3
3
35
Key Insights
Highlights
Success Rate
74% trial completion
Published Results
13 trials with published results (25%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 87/100
23.5%
12 terminated out of 51 trials
74.5%
-12.0% vs benchmark
0%
0 trials in Phase 3/4
37%
13 of 35 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 35 completed trials
Clinical Trials (51)
CAIX PET/ CT Guided Radiation Therapy in CcRCC.
SABR Combined With Targeted Therapy and Anti-PD-1 for Recurrent or Metastatic Renal Cancer
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors
flt3L With or Without Vaccine Therapy in Treating Patients With Metastatic Melanoma or Renal Cell Cancer
Monoclonal Antibody Therapy in Treating Patients With Advanced Kidney Cancer
Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Panobinostat and Everolimus in Treating Patients With Metastatic or Unresectable Renal Cell Cancer That Does Not Respond to Treatment With Sunitinib Malate or Sorafenib Tosylate
Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Kidney Cancer Undergoing Surgery
Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
CCI-779 and Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney Cancer
Autologous Dendritic Cells in Treating Patients With Metastatic Kidney Cancer
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer
Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
Low-Dose Total-Body Irradiation and Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Stage IV Kidney Cancer
Sunitinib Malate Related Fatigue in Patients With Metastatic Kidney Cancer